Keith A. Reynolds


Proper Coding Gets Practices What They Are Owed

A physician’s goal is to care for patients, but a key part of being able to provide that care is the eternal quest for payment. One way to ensure that a practice maximizes its coding regimen is to make sure each session can be efficiently billed.

Aaron Farberg, MD


Aaron Farberg, MD, Gears Up For Early Career Advice and Melanoma Sessions at Fall Clinical

Farberg is looking forward to another year of top-notch presentations at Fall Clinical 2023.

Gillian McGovern


Differences in Anti-PD-1/CTLA-4 and Anti-PD-1/LAG-3 Reported in Recent Study

The study examined the mechanisms of action associated with immune checkpoint inhibitor combination therapies.

Chris Ryan


Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy

China’s NMPA has approved tunlametinib for the treatment of patients with NRAS-mutated advanced melanoma after prior anti–PD-1/PD-L1 therapy.

Omar Noor, MD, FAAD


Case 2: Male, 58 Years Old with AD

Dr Omar Noor delves into the complexities of boxed warnings tied to JAK inhibitors, contrasting their presence in systemic forms with the absence in the oral version of topical ruxolitinib, and discusses the potential impact on dialogues with both patients and fellow healthcare providers. He further underscores the pivotal role of long-standing safety data in building provider confidence in a treatment.

Miranda Uzoma Ewelukwa, MD, FAAD


Improving Representation of Skin of Color in Dermatology

Miranda Uzoma Ewelukwa, MD, FAAD, reviews how skin of color representation has evolved in dermatology, however, more advocacy is still needed.

Viktoriya Avlasevich, PharmD


The Adalimumab Biosimiliar Pipeline: What's Ahead

FDA approvals of these biosimilars started in 2016, but only 1 such product has successfully launched.

Keith Algozzine


How a digital front door can improve patients’ access to care

Online-first engagement ensures patients obtain the right care for their specific needs.

Nanette Silverberg, MD


ReV Up Your Vitiligo Treatment Strategies

Nanette Silverberg, MD, takes a deep dive into the importance of early intervention and gave an overview of topical care for patients of all ages with vitiligo.

Brent Moody, MD, FACP, FAAD


Frontline Forum Part 4: Improving Basal Cell Carcinoma Management

In the final part of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, review 4 real-world clinical cases of BCC and the treatments they utilized.

Sherry G. Cohen, FNP-C, APRN-PMH


Sunscreen Protection for Children

Protection from the harsh rays of the sun is crucial for everyone—including children. Now that summer has arrived, a refresher course for your patients and their families on sun protection, which can go a long way in preventing skin damage and disorders due to the sun.

Dustin Portela, DO


Pointers With Portela: Effects of Hormone Changes on the Skin

In this week’s Pointers With Portela, the 208SkinDoc reviews how the skin is affected during hormonal changes and menopause.

Aaron S. Farberg, M.D., dermatologist, Baylor Scott & White Health System and Bare Dermatology in Dallas, Texas


Impact of Data on Generalized Pustular Psoriasis

Aaron S. Farberg, MD, and Jeffrey Crowley, MD, share take-home messages on the impact of the generalized pustular psoriasis study.

Jay A. Lieberman, MD, FACAAI


Jay A. Lieberman, MD, FACAAI: Clinical Pearls and Hands-On Educational Opportunities at ACAAI Annual Meeting

Program Chair Jay A. Lieberman, MD, provides a glimpse into the clinical pearls and dermatological educational opportunities presented at the ACAAI 2023 Annual Scientific Meeting.

Hailey Brickman, PA-C


Hypochlorous Acid: Is It Just a Trend? 

As someone who practices dermatology, it can often be difficult to determine if any of these new skin care trends are efficacious.

Linda Stein Gold, MD


Safety and Access Considerations: Topical Ruxolitinib Review

Dr Linda Stein-Gold and Dr Michael Cameron assess the safety and tolerability of topical ruxolitinib cream, offering guidance on counseling patients about the black box warning. They also address the perception of limited treatment access and strategies for overcoming this barrier.

Jennifer Conner, MPAS, PA-C


Take-Home Pearls on the Management of Plaque Psoriasis

Alexa Hetzel, MS, PA-C; Jennifer Conner, MPAS, PA-C; Terry Faleye, MPAS, PA-C; Laura Bush, DMSc, PA-C; and Lakshi Aldredge, MSN, ANP-BC, share take-home messages regarding the treatment of patients with plaque psoriasis, highlighting listening to and educating patients.

Tom Ferry, MBA


How Physicians Can Provide Better Care for Patients with Chronic Conditions

Technology and care navigators are key to managing this growing population

Lily Guo


Topical Steroid Withdrawal Syndrome Manifesting in Patients Treated for Atopic Dermatitis

Recent studies show patients are experiencing adverse effects of stopping corticosteroid treatment.

Bob Peelman


Do You Have the Right Financial Adviser?

Experts detail 5 tips to ask a financial advisor so they can best serve your interests.

James Q. Del Rosso, DO


Acne and Rosacea Pearls With Jim Del Rosso, DO, FAAD

The American Acne and Rosacea Society welcomed Del Rosso as its new president and he shared key takeaways from his AAD sessions.

Theresa A. Bingemann, MD, FACAA


Exploring the Diagnostics of Urticaria at ACAAI

Session at the American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Scientific Meeting explored issues in understanding and testing for physical urticaria.

Kim Papp, MD, PhD, FRCPC


Kim Papp, MD, PhD, FRCPC: Exploring the Potential of ESK-001 in Plaque Psoriasis

Papp shared insights from the recent STRIDE phase 2 trial, which met all its primary and secondary endpoints. Data was presented at the American Academy of Dermatology Annual Meeting.

James Song, MD, FAAD


Case 2: Male, 23 Years Old

An expert in dermatology presents the case of a 23-year-old male patient presenting with unstable vitiligo. He delves into treatment options available for managing this condition, shedding light on the nuances and optimal scenarios for each therapeutic agent.

Iltefat Hamzavi, MD


Late-Breaking Data: Upadacitinib for Vitiligo Achieves Skin Repigmentation Through Week 52

Iltefat Hamzavi, MD, reviews late-breaking data at AAD on upadacitinib as monotherapy.

© 2024 MJH Life Sciences

All rights reserved.